Biotechnology: Pharmaceutical Preparations

Equity OfferingApr 10, 2026, 08:31 AM

Annovis Bio Secures $10M Public Offering, Extends Cash Runway to Q2 2027, Funds NDA Submission with AD Phase 3 Trial 75% Enrolled

AI Summary

Annovis Bio, Inc. announced the closing of an underwritten public offering, raising approximately $10 million in gross proceeds. This financing, combined with existing cash and a $1.5 million investment from the Board Chair, extends the company's cash runway through Q2 2027. The funding is critical as it fully supports operations through the anticipated Q1 2027 6-month symptomatic data readout from its Phase 3 Alzheimer's disease trial, which is 75% enrolled, and the subsequent New Drug Application (NDA) submission for buntanetap. The company is also advancing an open-label Parkinson's disease study, which has enrolled 28% of participants, and is preparing for regulatory efficiency with the FDA agreeing to integrate safety data from both AD and PD populations for the AD NDA.

Key Highlights

Annovis Bio closed an underwritten public offering, generating approximately $10 million in gross proceeds.
The financing, combined with existing cash and a $1.5 million investment from Board Chair Michael Hoffman, extends the company's cash runway through Q2 2027.
The funding fully supports operations through the anticipated Q1 2027 6-month symptomatic data readout from the Phase 3 Alzheimer's disease (AD) trial and the subsequent NDA submission for buntanetap.
The pivotal Phase 3 AD trial (NCT06709014) is 75% enrolled and nearing completion.
An open-label extension (OLE) study in Parkinson's disease (PD) patients (NCT07284784) has enrolled 28% of participants since its inception in February 2026.
CEO Maria Maccecchini stated, "We now have the resources to reach our first major regulatory milestone: the 6-month data readout from our Phase 3 AD trial and the NDA submission that follows."

View SEC Filing

ANVS

Biotechnology: Pharmaceutical Preparations

Annovis Bio, Inc.

Price Impact